PMID- 36387340 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221118 IS - 1319-0164 (Print) IS - 2213-7475 (Electronic) IS - 1319-0164 (Linking) VI - 30 IP - 10 DP - 2022 Oct TI - Angelica Yinzi alleviates 1-chloro-2,4-dinitrobenzene-induced atopic dermatitis by inhibiting activation of NLRP3 inflammasome and down-regulating the MAPKs/NF-kB signaling pathway. PG - 1426-1434 LID - 10.1016/j.jsps.2022.07.003 [doi] AB - BACKGROUND: Atopic dermatitis (AD), characterized by eczema as a chronic pruritic inflammatory skin disease, has become a serious health problem with recurrent clinical episodes. However, current clinical treatments have limited relief and are accompanied by adverse effects. Therefore, there is a necessity to develop new effective drugs for AD treatment. Angelica Yinzi (AYZ) is a classic ancient prescription for nourishing blood, moistening dryness, dispelling wind, and relieving itching. However, its mechanism for alleviating atopic dermatitis remains unknown. Therefore, this study aimed at determining the effects of AYZ and its potential mechanism in alleviating AD-like symptoms. METHODS: In the present study, we used 1-chloro-2,4-dinitrobenzene (DNCB) to establish a mouse model of atopic dermatitis, where DNCB readily penetrates the epidermis to cause inflammation. Histopathological analysis was performed to examine the thickening of dorsal skin and infiltration in the inflammatory and mast cells in C57BL/6 mice. Additionally, the immunoglobulin E (IgE) levels in serum were determined by enzyme-linked immunosorbent assay (ELISA) kits. The IL-1beta and TNF-alpha expression were detected using qRT-PCR. Next, the Western blotting and immunohistochemistry assays were performed to assess the contribution of MAPKs/NF-kappaB signaling pathways and the NLRP3 inflammasome in AD responses. RESULTS: Histopathological examination revealed that AYZ reduced the epidermal thickness of AD-like lesioned skin and repressed the infiltration of mast cells into AD-like lesioned skin. AYZ significantly decreased the phosphorylation of p38 MAPK, JNK, ERK and NF-kappaB and downregulated serum IgE levels and IL-1beta and TNF-alpha mRNA levels. Additionally, the NLRP3, ASC, Caspase-1, and IL-1beta expression in dorsal skin were effectively down-regulated following AYZ treatment (p < 0.05 and p < 0.01). CONCLUSION: These findings revealed that AYZ effectively suppressed AD-induced skin inflammation by inhibiting the activation of the NLRP3 inflammasome and the MAPKs/NF-kB signaling. Therefore, AYZ is a potential therapeutic agent against AD in the clinical setting. CI - (c) 2022 The Author(s). FAU - Liu, Wei AU - Liu W AD - Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, PR China. AD - Post-doctoral Research Center of Mayinglong Pharmaceutical Group Co., Ltd., Wuhan, Hubei 430060, PR China. FAU - Song, Wanci AU - Song W AD - Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei 430065, PR China. FAU - Luo, Yang AU - Luo Y AD - Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei 430065, PR China. FAU - Dan, Hanxiong AU - Dan H AD - Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei 430065, PR China. FAU - Li, Li AU - Li L AD - Department of Pharmacy, Wuhan Hospital of Traditional Chinese Medicine, Wuhan, Hubei 430014, PR China. FAU - Zhang, Zhouyang AU - Zhang Z AD - Post-doctoral Research Center of Mayinglong Pharmaceutical Group Co., Ltd., Wuhan, Hubei 430060, PR China. FAU - Zhou, Daonian AU - Zhou D AD - Post-doctoral Research Center of Mayinglong Pharmaceutical Group Co., Ltd., Wuhan, Hubei 430060, PR China. FAU - You, Pengtao AU - You P AD - Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei 430065, PR China. LA - eng PT - Journal Article DEP - 20220719 PL - Saudi Arabia TA - Saudi Pharm J JT - Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society JID - 9705695 PMC - PMC9649345 OTO - NOTNLM OT - Angelica Yinzi OT - Atopic dermatitis OT - Inflammation OT - MAPK OT - NLRP3 COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/11/18 06:00 MHDA- 2022/11/18 06:01 PMCR- 2022/07/19 CRDT- 2022/11/17 11:58 PHST- 2021/12/30 00:00 [received] PHST- 2022/07/16 00:00 [accepted] PHST- 2022/11/17 11:58 [entrez] PHST- 2022/11/18 06:00 [pubmed] PHST- 2022/11/18 06:01 [medline] PHST- 2022/07/19 00:00 [pmc-release] AID - S1319-0164(22)00195-5 [pii] AID - 10.1016/j.jsps.2022.07.003 [doi] PST - ppublish SO - Saudi Pharm J. 2022 Oct;30(10):1426-1434. doi: 10.1016/j.jsps.2022.07.003. Epub 2022 Jul 19.